Literature DB >> 7172408

Characteristics of in vitro antiproliferation activity of human interferon-beta.

T Kataoka, F Oh-hashi, Y Sakurai, N Ida.   

Abstract

We compared the in vitro antiproliferative activity of highly purified interferon (IFN)-beta (greater than 10(7) U protein/mg in antiviral activity) with that of IFNs-alpha and lymphoblastoid, using human cells of malignant and non-malignant origin. IFN-beta was the least active of three IFNs in suppressing Daudi cell proliferation. Three hematological cells other than Daudi cells cultivated in suspension were insensitive to each of three IFNs. IFN-beta was more active than IFNs-alpha and lymphoblastoid in suppressing all eight epithelioid cells tested and, particularly with respect to five epithelioid cells sensitive to IFN, IFN-beta was seven to 49 times as active as IFN-alpha. These results indicate that suppression of cell proliferation by IFN depends not only on the target cell species but also on the IFN species, and emphasize the need for careful selection of the most appropriate IFN species in therapy. We found that the antiproliferative characteristics of the present IFN-beta preparation were consistent with those reported previously, supporting the idea that IFN-beta molecules in the present preparation were responsible for suppressing cell proliferation. The antiproliferation activity of our preparation was species-specific but not selective for cells of malignant origin; it was absorbable by IFN-sensitive but not by IFN-insensitive cells; and it was achieved by a cytostatic effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7172408     DOI: 10.1007/bf00265382

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Is interferon tissue specific?- Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines.

Authors:  S Einhorn; H Strander
Journal:  J Gen Virol       Date:  1977-06       Impact factor: 3.891

2.  Interferon, preclinical basis for clinical trials with fibroblast interferon in Japan.

Authors:  T Kataoka; Y Sakurai; N Ida; S Kobayashi
Journal:  Cancer Treat Rev       Date:  1980-12       Impact factor: 12.111

Review 3.  The clinical value of interferons as antitumor agents.

Authors:  A Billiau
Journal:  Eur J Cancer Clin Oncol       Date:  1981-09

4.  Effect of fibroblast, lymphoid, and myeloid interferons on human tumor colony formation in vitro.

Authors:  E C Bradley; F W Ruscetti
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

5.  Potentiation of antitumor effect of virus-induced interferon by mouse immune interferon preparations.

Authors:  W R Fleischmann; K M Kleyn; S Baron
Journal:  J Natl Cancer Inst       Date:  1980-11       Impact factor: 13.506

6.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

  6 in total
  4 in total

1.  Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3.

Authors:  J D Burke; L C Platanias; E N Fish
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

2.  Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro.

Authors:  B P Priosoeryanto; S Tateyama; R Yamaguchi; K Uchida
Journal:  Can J Vet Res       Date:  1995-01       Impact factor: 1.310

3.  Effect of interferon alpha, interferon beta, and interferon gamma on the in vitro growth of human renal adenocarcinoma cells.

Authors:  J P Kuebler; T D Oberley; L F Meisner; Y A Sidky; C A Reznikoff; E C Borden; K B Cummings; G T Bryan
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Differential modulating effects of retinoic acid on interferon antiviral activity.

Authors:  C K Ho; B R Ou; C Y Wang; H Y Chen; T Kuwata
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.